Newsfiscal.ai
NovaBridge Biosciences Reports Mature Phase 1b Data for Givastomig at ESMO 2026
· Published
Article summary
NovaBridge Biosciences presented updated Phase 1b clinical data for its bispecific antibody givastomig, supporting its advancement into registrational development for gastroesophageal adenocarcinoma.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…